Flaviano Giorgini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1380542/publications.pdf

Version: 2024-02-01

64 papers	8,374 citations	147801 31 h-index	102487 66 g-index
69 all docs	69 docs citations	69 times ranked	17811 citing authors

#	Article	IF	Citations
1	Cellular Localization of Kynurenine 3-Monooxygenase in the Brain: Challenging the Dogma. Antioxidants, 2022, 11, 315.	5.1	7
2	Therapeutic Targeting of Rab GTPases: Relevance for Alzheimerâ€™s Disease. Biomedicines, 2022, 10, 1141.	3.2	9
3	RAB39B is redistributed in dementia with Lewy bodies and is sequestered within aî² plaques and Lewy bodies. Brain Pathology, 2021, 31, 120-132.	4.1	11
4	Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases. Archives of Biochemistry and Biophysics, 2021, 697, 108702.	3.0	12
5	Mitochondrial SIRT3 confers neuroprotection in Huntington's disease by regulation of oxidative challenges and mitochondrial dynamics. Free Radical Biology and Medicine, 2021, 163, 163-179.	2.9	42
6	Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntingtonâ€™s disease. Scientific Reports, 2021, 11, 5484.	3.3	14
7	Dysfunction of <scp>RAB39Bâ€</scp>Mediated Vesicular Trafficking in Lewy Body Diseases. Movement Disorders, 2021, 36, 1744-1758.	3.9	12
8	Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease. Journal of Neurochemistry, 2021, 158, 539-553.	3.9	18
9	Inflammation control and improvement of cognitive function in COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition?. Drug Discovery Today, 2021, 26, 1473-1481.	6.4	20
10	Esculetin Provides Neuroprotection against Mutant Huntingtin-Induced Toxicity in Huntingtonâ€™s Disease Models. Pharmaceuticals, 2021, 14, 1044.	3.8	2
11	Tubulin and Tubulin Posttranslational Modifications in Alzheimerâ€™s Disease and Vascular Dementia. Frontiers in Aging Neuroscience, 2021, 13, 730107.	3.4	9
12	Rab8 Promotes Mutant HTT Aggregation, Reduces Neurodegeneration, and Ameliorates Behavioural Alterations in a Drosophila Model of Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2020, 9, 253-263.	1.9	8
13	A novel role for kynurenine 3-monooxygenase in mitochondrial dynamics. PLoS Genetics, 2020, 16, e1009129.	3.5	11
14	A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites. Communications Biology, 2019, 2, 271.	4.4	36
15	DJ-1 in Parkinsonâ€™s Disease: Clinical Insights and Therapeutic Perspectives. Journal of Clinical Medicine, 2019, 8, 1377.	2.4	101
16	Drosophila Nrf2/Keap1 Mediated Redox Signaling Supports Synaptic Function and Longevity and Impacts on Circadian Activity. Frontiers in Molecular Neuroscience, 2019, 12, 86.	2.9	31
17	The Parkinsonâ€™s Disease-Linked Protein DJ-1 Associates with Cytoplasmic mRNP Granules During Stress and Neurodegeneration. Molecular Neurobiology, 2019, 56, 61-77.	4.0	33
18	Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. Journal of Psychopharmacology, 2018, 32, 1223-1232.	4.0	11

#	Article	IF	Citations
19	Deubiquitinase Usp12 functions noncatalytically to induce autophagy and confer neuroprotection in models of Huntingtonâ€™s disease. Nature Communications, 2018, 9, 3191.	12.8	47
20	Assessing and Modulating Kynurenine Pathway Dynamics in Huntingtonâ€™s Disease: Focus on Kynurenine 3-Monooxygenase. Methods in Molecular Biology, 2018, 1780, 397-413.	0.9	8
21	Nitric oxide-mediated posttranslational modifications control neurotransmitter release by modulating complexin farnesylation and enhancing its clamping ability. PLoS Biology, 2018, 16, e2003611.	5.6	28
22	Adaptive and Behavioral Changes in Kynurenine 3-Monooxygenase Knockout Mice: Relevance to Psychotic Disorders. Biological Psychiatry, 2017, 82, 756-765.	1.3	57
23	Glycation potentiates Î±-synuclein-associated neurodegeneration in synucleinopathies. Brain, 2017, 140, 1399-1419.	7.6	153
24	Protein phosphatase 1 regulates huntingtin exon 1 aggregation and toxicity. Human Molecular Genetics, 2017, 26, 3763-3775.	2.9	32
25	Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5435-5440.	7.1	117
26	Glycation potentiates neurodegeneration in models of Huntingtonâ€™s disease. Scientific Reports, 2016, 6, 36798.	3.3	27
27	Connectivity mapping uncovers small molecules that modulate neurodegeneration in Huntingtonâ€™s disease models. Journal of Molecular Medicine, 2016, 94, 235-245.	3.9	14
28	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
29	shRNA-Based Screen Identifies Endocytic Recycling Pathway Components That Act as Genetic Modifiers of Alpha-Synuclein Aggregation, Secretion and Toxicity. PLoS Genetics, 2016, 12, e1005995.	3.5	68
30	Modeling Huntington Disease in Yeast and Invertebrates. , 2015, , 557-572.		0
31	The kynurenine pathway and neurodegenerative disease. Seminars in Cell and Developmental Biology, 2015, 40, 134-141.	5.0	223
32	Rab11 modulates Î±-synuclein-mediated defects in synaptic transmission and behaviour. Human Molecular Genetics, 2015, 24, 1077-1091.	2.9	94
33	Synapses and Î±-synuclein signalling in disease. Cogent Biology, 2015, 1, 1085295.	1.7	2
34	Yeast DJ-1 superfamily members are required for diauxic-shift reprogramming and cell survival in stationary phase. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 7012-7017.	7.1	45
35	A Drosophila RNAi collection is subject to dominant phenotypic effects. Nature Methods, 2014, 11, 222-223.	19.0	100
36	The small GTPase Rab11 co-localizes with Â-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity. Human Molecular Genetics, 2014, 23, 6732-6745.	2.9	73

#	Article	IF	Citations
37	Î±-Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner. Neurobiology of Disease, 2014, 70, 149-161.	4.4	84
38	Copy-number variation of the neuronal glucose transporter gene SLC2A3 and age of onset in Huntington's disease. Human Molecular Genetics, 2014, 23, 3129-3137.	2.9	38
39	Aggregation-Prone Proteins Modulate Huntingtin Inclusion Body Formation in Yeast. PLOS Currents, 2014, 6, .	1.4	5
40	Understanding neuronal dysfunction and loss in neurodegenerative disease. Journal of Molecular Medicine, 2013, 91, 651-652.	3.9	4
41	The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease. Journal of Molecular Medicine, 2013, 91, 705-713.	3.9	42
42	Parkinsonâ€™s disease-associated mutations in DJ-1 modulate its dimerization in living cells. Journal of Molecular Medicine, 2013, 91, 599-611.	3.9	31
43	Glutathione peroxidase activity is neuroprotective in models of Huntington's disease. Nature Genetics, 2013, 45, 1249-1254.	21.4	117
44	Targeted Deletion of Kynurenine 3-Monooxygenase in Mice. Journal of Biological Chemistry, 2013, 288, 36554-36566.	3.4	99
45	Structural basis of kynurenine 3-monooxygenase inhibition. Nature, 2013, 496, 382-385.	27.8	124
46	Rab11 as a modulator of synaptic transmission. Communicative and Integrative Biology, 2013, 6, e26807.	1.4	13
47	A flexible polyglutamine hinge opens new doors for understanding huntingtin function. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14516-14517.	7.1	8
48	Î²-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 107-124.	1.9	1
49	A Novel Sit4 Phosphatase Complex Is Involved in the Response to Ceramide Stress in Yeast. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-9.	4.0	6
50	Choosing and using Drosophila models to characterize modifiers of Huntington's disease. Biochemical Society Transactions, 2012, 40, 739-745.	3.4	17
51	Rab11 rescues synaptic dysfunction and behavioural deficits in a Drosophila model of Huntington's disease. Human Molecular Genetics, 2012, 21, 2912-2922.	2.9	68
52	Drosophila eye color mutants as therapeutic tools for Huntington disease. Fly, 2012, 6, 117-120.	1.7	34
53	Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration. Cell, 2011, 145, 863-874.	28.9	435
54	The Kynurenine Pathway Modulates Neurodegeneration in a Drosophila Model of Huntington's Disease. Current Biology, 2011, 21, 961-966.	3.9	231

#	Article	IF	Citations
55	Modeling Huntington disease in yeast: Perspectives and future directions. Prion, 2011, 5, 269-276.	1.8	49
56	Is modulating translation a therapeutic option for Huntingtonâ€™s disease?. Neurodegenerative Disease Management, 2011, 1, 89-91.	2.2	1
57	Functional Gene Expression Profiling in Yeast Implicates Translational Dysfunction in Mutant Huntingtin Toxicity. Journal of Biological Chemistry, 2011, 286, 410-419.	3.4	51
58	Modeling Huntington disease in yeast: Perspectives and future directions. Prion, 2011, 5, 269-276.	1.8	27
59	Targeting Kynurenine 3-Monooxygenase (KMO): Implications for Therapy in Huntingtons Disease. CNS and Neurological Disorders - Drug Targets, 2010, 9, 791-800.	1.4	71
60	Histone Deacetylase Inhibition Modulates Kynurenine Pathway Activation in Yeast, Microglia, and Mice Expressing a Mutant Huntingtin Fragment. Journal of Biological Chemistry, 2008, 283, 7390-7400.	3.4	86
61	Yeast as a drug discovery platform in Huntington's and Parkinson's diseases. Biotechnology Journal, 2006, 1, 258-269.	3.5	48
62	A network of protein interactions determines polyglutamine toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11051-11056.	7.1	141
63	A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nature Genetics, 2005, 37, 526-531.	21.4	323
64	Connecting the dots in Huntington's disease with protein interaction networks. Genome Biology, 2005, 6, 210.	9.6	35